Technology
Health
Pharmaceutical

Moleculin Biotech

$1.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.89%) Today
-$0.02 (-1.80%) After Hours

Why Robinhood?

You can buy or sell MBRX and other stocks, options, ETFs, and crypto commission-free!

About

Moleculin Biotech, Inc. Common Stock, also called Moleculin Biotech, is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Read More Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Employees
9
Headquarters
Houston, Texas
Founded
2015
Market Cap
38.19M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.15M
High Today
$1.13
Low Today
$1.09
Open Price
$1.12
Volume
211.76K
52 Week High
$3.15
52 Week Low
$0.7772

Collections

Technology
Health
Pharmaceutical
Medical
2016 IPO
US
North America

News

PR NewswireMay 7

Biotech Stocks: Why Expensive U.S. Drug Trials are Pushing Pharma Research Overseas

PALM BEACH, Florida, May 7, 2019 /PRNewswire/ -- American pharmaceutical and biotech companies who need to conduct clinical trials are looking more and more to conduct them overseas in the European Union, because the EU offers lower cost alternatives to U.S. trials… which not only saves money, buy also can save time to market.

1,130
PR NewswireMay 7

Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe

HOUSTON, May 7, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. After receiving a single starting dose of 120 mg/m2 in the first cohort of the dose escalation phase of the trial, 2 of 3 patients treate...

744
PR NewswireApr 29

US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

HOUSTON, April 29, 2019 /PRNewswire/ -- A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland, speeding the process of patient recruitment and data collection.

2,709

Earnings

-$0.20
-$0.13
-$0.07
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.09 per share
Actual
-$0.14 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.